International bodies call for human rights-led AI in healthcare. Learn how HUDERIA, the Oviedo Convention and multi-stakeholder oversight can protect patients and support clinicians.
AI in Healthcare: Building Trust Through Human Rights Read More »
New AI platforms are shortening drug discovery timelines and shifting R&D priorities. What biotech and pharma leaders need to know now.
AI’s Immediate Impact on Drug Discovery: A Focused Update for Biotech Leaders Read More »
UK health and social care regulators, including the PSA and GPhC, commit to joint AI guidance focused on patient safety, public trust, human oversight, and accountability.
UK Health Regulators Unite on AI Guidance to Protect Patients and Professional Judgment Read More »
Anthropic expands verified access to advanced AI for life sciences and reports Claude-driven speedups in biomolecular modeling, raising governance and biosecurity questions.
Anthropic’s Dual Leap: Controlled Access and Faster Biomolecular Modeling with Claude Read More »
Frontline nurses are shaping AI in healthcare, from monitoring and documentation to ethics and governance. Nursing leadership will guide responsible, equitable AI.
Nurses Leading AI Innovation in Healthcare: Patient Care, Ethics, and Collaboration Read More »
DataMEDS AI extinguished roughly $19M in liabilities, launched a new site and acquired Helomics’ AI cancer diagnostics lab to refocus on AI-driven oncology diagnostics.
DataMEDS AI Repositions for AI Oncology Diagnostics with Helomics Read More »
AI in healthcare raises hard questions about liability. Using recent UK reports as a case study, this piece outlines legal gaps, emerging policy options, and practical steps for providers and developers.
Who Pays When AI in Healthcare Causes Harm? Liability Lessons from the UK Read More »
Explore how AI is tailoring treatments with genomic insights, faster drug discovery, and precision diagnostics. What comes next for patient-centered care?
How AI Is Transforming Personalized Medicine: Genomics, Drugs, Diagnostics Read More »
ByteDance’s Anew Labs raised $290M at a $1.5B valuation to accelerate AI-driven drug discovery with models Protenix and PXDesign. Series A led by HSG and others.
ByteDance’s Anew Labs Raises $290M at $1.5B Valuation to Scale AI Drug Discovery Read More »
How AI shortens drug discovery timelines, improves candidate selection, and reshapes pharma R&D with real examples and strategic implications.
AI Drug Discovery: How Machine Learning Is Speeding Pharma R&D Read More »
